BD1.AX - BARD1 Life Sciences Limited

ASX - ASX Delayed price. Currency in AUD

BARD1 Life Sciences Limited

Harry Perkins Institute of Medical Research
L2/QQ Block 6 Verdun Street
Nedlands, WA 6009
61 8 9381 9550

IndustryDiagnostics & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Peter Lynton Gunzburg B Comm, ASIAExec. Chairman & MD75.28kN/A1952
Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.Chief Exec. Officer389.4kN/AN/A
Dr. Irmgard Irminger-FingerFounder, Exec. Director & Chief Scientific Officer150kN/AN/A
Ms. Pauline Anne CollinsonCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


BARD1 Life Sciences Limited focuses on developing and commercializing non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a non-invasive blood test for screening and diagnosing lung cancer at early stages of disease progression. The company is also developing BARD1 ovarian cancer test, a non-invasive blood test for early detection of ovarian cancer. It has a collaboration agreement with Institute for Respiratory Health to evaluate a BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models; and Thermo Fisher Scientific to develop multiplex autoantibody assay. BARD1 Life Sciences Limited is headquartered in Nedlands, Australia.

Corporate governance

BARD1 Life Sciences Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.